What happened with NAMS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
NewAmsterdam Pharma is developing a once-daily oral treatment for patients whose LDL cholesterol remains elevated despite existing cholesterol-lowering therapy. Its only drug candidate, obicetrapib, is being developed both alone and in a single tablet with ezetimibe, primarily as an addition to statins. The company has no approved products and cannot market obicetrapib before regulatory approval.
Menarini is its only revenue-generating partner. Revenue comes mainly from their license agreement, which provides upfront and development payments and payments tied to clinical, regulatory and commercial milestones. Menarini holds exclusive rights to the licensed products in most European countries and handles local approvals and commercialization. If approved and sold there, NewAmsterdam would also receive royalties on sales. It supplies Menarini with drug products and ingredients at a markup over production cost, but supply contributes much less revenue than the license agreement.
NewAmsterdam retains rights elsewhere and is building its own U.S. commercial organization for a potential launch. It relies on contract manufacturers rather than its own factories. Its business depends on obicetrapib gaining approval and on Menarini bringing it to market in its licensed territory.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
NewAmsterdam Pharma’s results hinge on obicetrapib’s approval and uptake; watch Menarini, which supplies its current revenue and holds exclusive commercialization rights across most of Europe.
Merck’s oral cholesterol-lowering candidate enlicitide could compete directly with NewAmsterdam Pharma’s oral obicetrapib for patients whose LDL-C remains high despite statins. Merck released completed Phase 3 data in November 2025; watch whether enlicitide gains approval, which could allow a U.S. launch in 2026.
AstraZeneca’s oral cholesterol-lowering candidate AZD0780 targets the same LDL-C-lowering market as NewAmsterdam Pharma’s oral obicetrapib. Its ongoing Phase 3 trial is the development to watch for another potential oral alternative.
Novartis already sells Leqvio to lower LDL-C in patients NewAmsterdam Pharma hopes to reach with obicetrapib, making it an established alternative for that overlapping patient group.
Regeneron markets the LDL-C-lowering medicine Praluent to patients NewAmsterdam Pharma intends to treat with obicetrapib, so obicetrapib would face an existing treatment competing for those patients.
Alnylam receives a share of Leqvio sales as royalties, tying part of its income to a cholesterol-lowering medicine that would compete with NewAmsterdam Pharma’s obicetrapib if approved.
Ionis Pharmaceuticals’ pelacarsen overlaps NewAmsterdam Pharma’s potential cardiovascular-risk treatment market, targeting cardiovascular patients with elevated lipoprotein(a), or Lp(a). Watch pelacarsen’s development in that patient group: Ionis identifies obicetrapib as a potential competitor there.
Arrowhead’s candidates to lower LDL-C and Lp(a) in patients with atherosclerotic cardiovascular disease could compete with NewAmsterdam Pharma’s obicetrapib for cardiovascular-risk treatment. Watch those candidates’ development rather than sales of REDEMPLO, its approved medicine for lowering triglycerides in adults with familial chylomicronemia syndrome.
Novartis AG earningsNVS
Novartis’s report will show Leqvio sales, indicating whether patients who overlap with NewAmsterdam Pharma’s target group are using this alternative LDL-C-lowering treatment.
Check the Leqvio sales Novartis reports. Stronger sales would show greater use of an established alternative among overlapping patients; weaker sales would show less current sales traction, not that those patients would switch to obicetrapib. For NewAmsterdam Pharma, this is evidence about the treatment landscape, not proof of demand for its candidate.
NewAmsterdam Pharma Company N.V. earningsThis company
NewAmsterdam Pharma still relies on cash to develop obicetrapib, and this report will show whether research spending is matched by progress toward approval.
Read research and development spending alongside cash and marketable securities, then check for reported clinical or regulatory progress on obicetrapib. Higher spending with progress would show cash funding the program’s advance; higher spending without much progress would mean faster cash use with less development progress to show for it.
